Integrative pipeline to profile and target endocrine therapy-insensitive cell populations in ER+ breast cancer
Up to 40% of patients with estrogen receptor positive breast cancer will experience relapse, either while on endocrine therapy (ET) or after ET is completed. A major contributor to ET failure is the presence of ET-insensitive cell populations within tumors. Here, we developed an analytical pipeline to systematically identify and target these populations by integrating single-cell RNA sequencing…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
